The therapeutic potential of oral creatine supplementation in muscle disease

Medical Hypotheses

Volumn 51, Issue 4, 1998, Pages 333-336

  Wyss, M ^a,c   Felber, S ^a   Skladal, D ^a   Koller, A ^a   Kremser, C ^a   Sperl, W ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Children's Hospital Salzburg   (Austria)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CARRIER PROTEIN; CHLORIDE ION; CREATINE; CREATINE KINASE; CREATINE PHOSPHATE; DYSTROPHIN; GLYCOGEN; GUANIDINOPROPIONIC ACID; PHOSPHATE; SODIUM ION;

DUCHENNE MUSCULAR DYSTROPHY; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION;

EID: 0031786712     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90058-5     Document Type: Article

References (37)

1. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger H M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281: 21-40.
2. Wyss M, Smeitink J, Wevers R A, Wallimann T. Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. Biochim Biophys Acta 1992; 1102: 119-166.
3. van Deursen J, Heerschap A, Oerlemans F et al. Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell 1993; 74: 621-631.
4. van Deursen J, Ruitenbeek W, Heerschap A, Jap P, ter Laak H, Wieringa B. Creatine kinase (CK) in skeletal muscle energy metabolism: a study of mouse mutants with graded reduction in muscle CK expression. Proc Natl Acad Sci USA 1994; 91: 9091-9095.
5. Ventura-Clapier R, Kuznetsov A V, d'Albis A, van Deursen J, Wieringa B, Veksler V I. Muscle creatine kinase-deficient mice. I. Alterations in myofibrillar function. J Biol Chem 1995; 270: 19914-19920.
6. Feeback D L, Locklear I, Brumback R A. Metabolic myopathy produced by dinitrofluorobenzene inhibition of creatine phosphokinase. J Neurol Sci 1988; 88: 219-228.
7. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 1994; 133/134: 51-66.
8. Otten J V, Fitch C D, Wheatley J B, Fischer V W. Thyrotoxic myopathy in mice: accentuation by a creatine transport inhibitor. Metabolism 1986; 35: 481-484.
9. Bourdakos N, Wolf S. Creatine and muscular dystrophy. Relationship of creatine-creatinine metabolism to diet and drags. Arch Neurol 1962; 6: 439-450.
10. Dioszeghy P. Determination of creatine kinase activity and related problems in neuromuscular diseases. In: De Deyn P P, Marescau B, Stalon V, Qureshi I A, eds. Guanidino Compounds in Biology and Medicine. London: John Libbey, 1992: 223-230.
11. Levene P A, Kristeller L. Factors regulating the creatinin output in man. Am J Physiol 1909; 24: 45-65.
12. Milhorat A T, Wolff H G. Studies in diseases of muscle. IV. Metabolism of creatine and creatinine in muscular wasting subsequent to disease of the nervous system. Arch Neurol Psychiatr 1938; 40: 663-679.
13. Milhorat A T, Wolff H G. Studies in diseases of muscle. V. Metabolism of creatine and creatinine in myotonia congenita, myotonia atrophica, amyotonia congenita, dystonia musculorum deformans and paralysis agitans. Arch Neurol Psychiatr 1938; 40: 680-698.
14. Reinhold J G, Kingsley G R. The chemical composition of voluntary muscle in muscle disease: a comparison of progressive muscular dystrophy with other diseases together with a study of effects of glycine and creatine therapy. J Clin Invest 1938; 17: 377-383.
15. Vignos P J, Warner J L. Glycogen, creatine, and high energy phosphate in human muscle disease. J Lab Clin Med 1963; 62: 579-590.
16. Whedon G D, Shorr E. Metabolic studies in paralytic acute anterior poliomyelitis. I. Alterations in nitrogen and creatine metabolism. J Clin Invest 1957; 36: 942-965.
17. Edwards R H T. Energy metabolism in normal and dystrophic human muscle. In: Rowland L P, ed. Pathogenesis of Human Muscular Dystrophies. Amsterdam: Excerpta Medica, 1977: 415-429.
18. Fitch C D. Significance of abnormalities of creatine metabolism. In: Rowland L P, ed. Pathogenesis of Human Muscular Dystrophies. Amsterdam: Excerpta Medica, 1977: 328-340.
19. Pennington R J T. Clinical biochemistry of muscular dystrophy. Br Med J 1980; 36: 123-126.
20. Peters J P, van Slyke D D, eds. Quantitative Clinical Chemistry, Interpretations, VoI I, 2nd edn. Baltimore, MD: Williams & Wilkins, 1946.
21. +-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. J Biol Chem 1993; 268: 8418-8421.
22. Loike J D, Zalutsky D L, Kaback E, Miranda A F, Silverstein S C. Extracellular creatine regulates creatine transport in rat and human muscle cells. Proc Natl Acad Sci USA 1988; 85: 807-811.
23. Cooper A C, Miller J R. Progressive muscular dystrophy: a review. Rev Can Biol 1962; 21: 337-351.
24. Duncan C J. Dystrophin and the integrity of the sarcolemma in Duchenne muscular dystrophy. Experientia 1989; 45: 175-177.
25. Dunn J F, Bannister N, Kemp G J, Publicover S J. Sodium is elevated in mdx muscles: ionic interactions in dystrophic cells. J Neurol Sci 1993; 114: 76-80.
26. 2+ is elevated at all ages. J Neurol Sci 1991; 103: 226-231.
27. Gillis J M. Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Acta Physiol Scand 1996; 156: 397-406.
28. Turner P R, Fong P, Denetclaw W F, Steinhardt R A. Increased calcium influx in dystrophic muscle. J Cell Biol 1991; 115: 1701-1712.
29. Benders A A G M, Wevers R A, Veerkamp J H. Ion transport in human skeletal muscle cells: disturbances in myotonic dystrophy and Brody's disease. Acta Physiol Scand 1996; 156: 355-367.
30. Mounsey J P, Xu P, John J E et al. Modulation of skeletal muscle sodium channels by human myotonin protein kinase. J Clin Invest 1995; 95: 2379-2384.
31. Rüdel R, Ricker K, Lehmann-Horn F. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol 1993; 50: 1241-1248.
32. Balsom P D, Söderlund K, Sjödin B, Ekblom B. Skeletal muscle metabolism during short duration high-intensity exercise: influence of creatine supplementation. Acta Physiol Scand 1995; 154: 303-310.
33. Birch R, Noble D, Greenhaff P L. The influence of dietary creatine supplementation on performance during repeated bouts of maximal isokinetic cycling in man. Eur J Appl Physiol 1994; 69: 268-270.
34. Earnest C P, Snell P G, Rodriguez R, Almada A L, Mitchell T L. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol Scand 1995; 153: 207-209.
35. Harris R C, Söderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992; 83: 367-374.
36. Khan M A. Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 1993; 120: 8-14.
37. Scholte H R, Rodrigues Pereira R, Busch H F M, Jennekens F G I, Luyt-Houwen I E M, Vaandrager-Verduin M H M. Carnitine deficiency, mitochondrial dysfunction and the heart. Identical defect of oxidative phosphorylation in muscle mitochondria in cardiomyopathy due to carnitine loss and in Duchenne muscular dystrophy. Wiener Klin Wochenschr 1989; 101: 12-17.